Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Novartis discovers AKR1C3-dependent GTPase KRAS inhibitors

Feb. 4, 2021

Cybrexa 3 patents peptide conjugates of microtubule-targeting agents

Feb. 4, 2021

New cannabinoid CB1 and CB2 receptor ligands identified at Canopy Growth Corp.

Feb. 4, 2021

DexTech expands preclinical program to evaluate OsteoDex in multiple myeloma

Feb. 3, 2021

Curis initiates phase II LUCAS study of CA-4948 as treatment for anemia in MDS

Feb. 3, 2021

Phase I data presented for AXL inhibitor DS-1205c plus osimertinib in EGFR-mutated NSCLC

Feb. 3, 2021

Annamycin shows significant therapeutic benefit in metastatic osteosarcoma animal model

Feb. 3, 2021

WCLC 2021: KRAS drugs may do best in tough subtype

Feb. 2, 2021

Updated results presented from TRIDENT-1 study of repotrectinib

Feb. 2, 2021

Mobocertinib shows clinical benefit in patients with exon 20-mutated NSCLC

Feb. 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...